Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update

Daniela Adamo, Elena Calabria, Noemi Coppola, Giuseppe Pecoraro, Michele Davide Mignogna, Daniela Adamo, Elena Calabria, Noemi Coppola, Giuseppe Pecoraro, Michele Davide Mignogna

Abstract

Chronic neuropathic pain (CNP) is a disabling medical condition that impairs the health-related quality-of-life of affected patients. A high prevalence of anxiety, depression, sleep disturbance and cognitive impairment has frequently been reported in association with CNP, making the management of this disease complex and often multidisciplinary. Dual-acting agents such as selective serotonin and noradrenalin reuptake inhibitors (SNRIs) are considered particularly useful in the modulation of pain and in treatment of the mood disorders frequently associated with CNP. Recent evidence suggests that the top-down inhibitory control of pain involves the engagement and enhancement of descending endogenous opioidergic, cannabinoid and serotonergic systems, with the effect of serotonin being particularly related to the receptor subtypes that are preferentially activated; indeed serotonin induces analgesia via activation of 5-HT7 receptors and hyperalgesia via activation of 5-HT3 receptors. Vortioxetine (VO) is a novel multimodal serotonergic antidepressant with a unique mechanism of action. It has been demonstrated recently in experimental and clinical studies to have efficacy on pain hypersensitivity and on mood disorders. This drug inhibits the serotonin transporter with a high affinity, antagonises the 5-HT3, 5-HT1D and 5HT7 serotonin receptors, and activates the 5-HT1A and 5-HT1B receptors. In clinical studies, VO has proved effective at a dose of 10-20 mg/daily in short- and long-term treatment of patients with chronic orofacial pain, demonstrating a higher rate of clinical response and remission, a better acceptability, safety rate and tolerability, and a lower latency of action compared with other antidepressants. In the light of these recent findings, VO may be considered as a new pharmacological treatment also in relation to various types of CNP, particularly in elderly patients with concomitant mood disorders and cognitive impairment. The purpose of this review is to provide an up-to-date overview of the pharmacology and clinical applications of VO and to highlight its potential therapeutic properties and advantages in the management of CNP.

Keywords: anxiety; chronic neuropathic pain; cognitive impairment; depression; vortioxetine.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

© The Author(s), 2021.

References

    1. Sá KN, Moreira L, Baptista AF, et al.Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain Rep 2019; 4: e779.
    1. McWilliams DF, Walsh DA. Pain mechanisms in rheumatoid arthritis. Clin Exp Rheumatol 2017; 35 Suppl107: 94–101.
    1. Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev 2018; 70: 315–347.
    1. IASP Taxonomy. (2011). International Association for the study of pain. IASP Publications, (, accessed 16 January 2015).
    1. Colloca L, Ludman T, Bouhassira D, et al.Neuropathic pain. Nat Rev Dis Primers 2017; 3: 17002. Published 2017 Feb 16.
    1. Yalcin I, Barthas F, Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev 2014; 47: 154–164.
    1. Torta R, Ieraci V, Zizzi F. A review of the emotional aspects of neuropathic pain: from comorbidity to co-pathogenesis. Pain Ther 2017; 6: 11–17.
    1. Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med 2004; 5: S9–S27.
    1. Radat F, Margot-Duclot A, Attal N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. Eur J Pain 2013; 17: 1547–1557.
    1. Humo M, Lu H, Yalcin I. The molecular neurobiology of chronic pain-induced depression. Cell Tissue Res 2019; 377: 21–43.
    1. Finnerup NB, Attal N, Haroutounian S, et al.Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 162–173.
    1. Attal N, Cruccu G, Baron R, et al.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113–e88.
    1. Więdłocha M, Marcinowicz P, Krupa R, et al.Effect of antidepressant treatment on peripheral inflammation markers: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2018; 80: 217–226.
    1. Wattiez AS, Dupuis A, Privat AM, et al.Disruption of 5-HT 2A -PDZ protein interaction differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in rats. Neuropharmacol 2017; 125: 308–318.
    1. Dupuis A, Wattiez AS, Pinguet J, et al.Increasing spinal 5-HT 2A receptor responsiveness mediates anti-allodynic effect and potentiates fluoxetine efficacy in neuropathic rats. Evidence for GABA release. Pharmacol Res 2017; 118: 93–103.
    1. Sindrup SH, Gram LF, Brøsen K, et al.The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135–144.
    1. Giannopoulos S, Kosmidou M, Sarmas I, et al.Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. Clin J Pain 2007; 23: 267–269.
    1. Wang SM, Han C, Bahk WM, et al.Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J 2018; 54: 101–112.
    1. Urits I, Peck J, Orhurhu MS, et al.Off-label antidepressant use for treatment and management of chronic pain: evolving understanding and comprehensive review. Curr Pain Headache Rep 2019; 23: 66.
    1. Food and Drug Administration. BrintellixTM (vortioxetine) tablets for oral use. Full prescribing information, (2013, accessed 13 February 2021).
    1. European Medicines Agency. EPAR brintellix product information. Annex I. Summary of product characteristics, (2014, accessed 13 Feruary 2021).
    1. WHO Collaborating Centre for Drug Statistics Methodology. Oslo: ATC classification index with DDDs,
    1. Micov AM, Tomić MA, Todorović MB, et al.Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. Prog Neuropsychopharmacol Biol Psychiatry 2020; 103: 109975.
    1. Salagre E, Grande I, Solé B, et al.Vortioxetine: a new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment 2018; 11: 48–59.
    1. Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, et al.Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 2017; 69: 595–601.
    1. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015; 145: 43–57.
    1. Riga MS, Sánchez C, Celada P, et al.Involvement of 5-HT 3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacol 2016; 108: 73–81.
    1. Frampton JE. Vortioxetine: a review in cognitive dysfunction in depression. Drugs 2016; 76: 1675–1682.
    1. Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov 2019; 14: 81–89.
    1. Pehrson AL, Hillhouse TM, Haddjeri N, et al.Task- and treatment length-dependent effects of vortioxetine on scopolamine-induced cognitive dysfunction and Hippocampal extracellular acetylcholine in rats. J Pharmacol Exp Ther 2016; 358: 472–482.
    1. Mørk A, Pehrson A, Brennum LT, et al.Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340: 666–675.
    1. Lecours M, El Mansari M, Blier P. P.2.b.015 electrophysiological effects of the multimodal antidepressant Lu AA21004 on serotonin transmission in the rat hippocampus. Eur Neuropsychopharmacol 2012; 22: S249.
    1. Bonaventure P, Dugovic C, Kramer M, et al.Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther 2012; 342: 429–440.
    1. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 2013; 23: 1190–1198.
    1. Vahid-Ansari F, Zhang M, Zahrai A, et al.Overcoming resistance to selective serotonin reuptake inhibitors: targeting serotonin, serotonin-1A receptors and adult neuroplasticity. Front Neurosci 2019; 13: 404.
    1. Okada M, Okubo R, Fukuyama K. Vortioxetine subchronically activates serotonergic transmission via desensitization of Serotonin 5-HT1A receptor with 5-HT3 receptor inhibition in rats. Int J Mol Sci 2019; 20: 6235.
    1. El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015; 232: 2343–2352.
    1. Okubo R, Hasegawa T, Fukuyama K, et al.Current limitations and candidate potential of 5-HT7 receptor antagonism in psychiatric pharmacotherapy. Front Psychiatry 2021; 12: 623684.
    1. du Jardin KG, Jensen JB, Sanchez C, et al.Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014; 24: 160–171.
    1. Jensen JB, du Jardin KG, Song D, et al.Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol 2014; 24: 148–159.
    1. Wallace A, Pehrson AL, Sánchez C, et al.Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014; 17: 1695–1706.
    1. Jiang LX, Huang GD, Su F, et al.Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice. Psychopharmacology (Berl) 2020; 237: 1233–1243.
    1. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014; 17: 1557–1567.
    1. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al.A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015; 232: 2061–2070.
    1. McIntyre RS, Harrison J, Loft H, et al.The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol 2016; 19: w055.
    1. McIntyre RS, Florea I, Tonnoir B, et al.Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry 2017; 78: 115–121.
    1. Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol 2018; 21: 97–107.
    1. Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018; 227: 803–809.
    1. Freeman MP, Cheng LJ, Moustafa D, et al.Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Ann Clin Psychiatry 2017; 29: 249–257.
    1. Smith J, Browning M, Conen S, et al.Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 2018; 23: 1127–1133.
    1. Areberg J, Luntang-Jensen M, Søgaard B, et al.Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 2012; 110: 401–404.
    1. Nierenberg AA, Loft H, Olsen CK. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: a randomized, double-blinded, exploratory study with vortioxetine. J Affect Disord 2019; 250: 35–42.
    1. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 2016; 19: v082.
    1. Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. J Affect Disord 2019; 250: 114–122.
    1. Bennabi D, Haffen E, Van Waes V. Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research. Front Psychiatry 2019; 10: 771. Published 2019 Nov 6.
    1. Kugathasan P, Waller J, Westrich L, et vivo and in vitro effects of vortioxetine on molecules associated with neuroplasticity. J Psychopharmacol 2017; 31: 365–376.
    1. Smagin GN, Song D, Budac DP, et al.Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2016; 68: 25–30.
    1. Bang-Andersen B, Ruhland T, Jørgensen M, et al.Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011; 54: 3206–3221.
    1. Díaz-Mataix L, Scorza MC, Bortolozzi A, et al.Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005; 25: 10831–10843.
    1. Micheli L, Ceccarelli M, D’Andrea G, et al.Depression and adult neurogenesis: positive effects of the antidepressant fluoxetine and of physical exercise. Brain Res Bull 2018; 143: 181–193.
    1. Mateus-Pinheiro A, Pinto L, Bessa JM, et al.Sustained remission from depressive-like behavior depends on hippocampal neurogenesis. Transl Psychiatry 2013; 3: e210.
    1. Lu Y, Ho CS, McIntyre RS, et al.Effects of vortioxetine and fluoxetine on the level of brain derived neurotrophic factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Res Bull 2018; 142: 1–7.
    1. Waller JA, Chen F, Sánchez C. Vortioxetine promotes maturation of dendritic spines in vitro: a comparative study in hippocampal cultures. Neuropharmacol 2016; 103: 143–154.
    1. Bétry C, Pehrson AL, Etiévant A, et al.The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. Int J Neuropsychopharmacol 2013; 16: 1115–1127.
    1. Guilloux JP, Mendez-David I, Pehrson A, et al.Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacol 2013; 73: 147–159.
    1. Adamo D, Sardella A, Varoni E, et al.The association between burning mouth syndrome and sleep disturbance: a case-control multicentre study. Oral Dis 2018; 24: 638–649.
    1. Goldstein DJ, Lu Y, Detke MJ, et al.Duloxetine vs. Placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109–118.
    1. Papandreou C, Skapinakis P, Giannakis D, et al.Antidepressant drugs for chronic urological pelvic pain: an evidence-based review. Adv Urol 2009; 2009: 1–9.
    1. Zuena AR, Maftei D, Alemà GS, et al.Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain 2018; 14: 1–9. DOI: 10.1177/1744806918808987.
    1. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215–235.
    1. Pacher P, Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem 2004; 11: 925–943.
    1. Fanburg BL, Lee SL. A role for the serotonin transporter in hypoxia-induced pulmonary hypertension. J Clin Investig 2000; 105: 1521–1523.
    1. Matsumoto M, Yoshioka M, Togashi H, et al.Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 1995; 272: 1044–1051.
    1. Suwabe A, Kubota M, Niwa M, et al.Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats. Brain Res 2000; 858: 393–401.
    1. Chen M, Hoshino H, Saito S, et al.Spinal dopaminergic involvement in the antihyperalgesic effect of antidepressants in a rat model of neuropathic pain. Neurosci Lett 2017; 649: 116–123.
    1. Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci 2017; 18: 2483.
    1. Pertovaara A, Almeida A. Chapter 13 descending inhibitory systems. Handb Clin Neurol 2006; 81: 179–192.
    1. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002; 25: 319–325.
    1. Lv Q, Wu F, Gan X, et al.The involvement of descending pain inhibitory system in electroacupuncture-induced analgesia. Front Integr Neurosci 2019; 13: 38.
    1. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Investig 2010; 120: 3779–3787.
    1. Nasirinezhad F, Hosseini M, Karami Z, et al.Spinal 5-HT3 receptor mediates nociceptive effect on central neuropathic pain; possible therapeutic role for tropisetron. J Spinal Cord Med 2016; 39: 212–219.
    1. Leiser SC, Pehrson AL, Robichaud PJ, et al.Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine: a quantitative EEG study in rats. Br J Pharmacol 2014; 171: 4255–4272.
    1. Viguier F, Michot B, Hamon M, et al.Multiple roles of serotonin in pain control mechanisms: implications of 5-HT₇ and other 5-HT receptor types. Eur J Pharmacol 2013; 716: 8–16.
    1. Avila-Rojas SH, Velázquez-Lagunas I, Salinas-Abarca AB, et al.Role of spinal 5-HT5A, and 5-HT1A/1B/1D, receptors in neuropathic pain induced by spinal nerve ligation in rats. Brain Res 2015; 1622: 377–385.
    1. Sagalajev B, Bourbia N, Beloushko E, et al.Bidirectional amygdaloid control of neuropathic hypersensitivity mediated by descending serotonergic pathways acting on spinal 5-HT3 and 5-HT1A receptors. Behav Brain Res 2015; 282: 14–24.
    1. Yang S, Chang MC. Chronic pain: structural and functional changes in brain structures and associated negative affective states. Int J Mol Sci 2019; 20: 3130.
    1. Dhikav V, Anand K. Hippocampus in health and disease: an overview. Ann Indian Acad Neurol 2012; 15: 239–246.
    1. Holderbach R, Clark K, Moreau JL, et al.Enhanced long-term synaptic depression in an animal model of depression. Biol Psychiatry 2007; 62: 92–100.
    1. Neto FL, Borges G, Torres-Sanchez S, et al.Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol 2011; 9: 530–552.
    1. Zhang H, Qian YL, Li C, et al.Brain-derived neurotrophic factor in the Mesolimbic reward circuitry mediates nociception in chronic neuropathic pain. Biol Psychiatry 2017; 82: 608–618.
    1. Sun B, Lv Y, Xu H, et al.Effects of vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus. Exp Ther Med 2020; 20: 2895–2902.
    1. Carta MG, Pala AN, Finco G, et al.Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemol Ment Health 2015; 11: 144–149.
    1. Talmon M, Rossi S, Pastore A, et al.Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol 2018; 175: 113–124.
    1. Tomaz VDS, Chaves Filho AJM, Cordeiro RC, et al.Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord 2020; 268: 188–200.
    1. Xu N, Tang XH, Pan W, et al.Spared nerve injury increases the expression of microglia M1 markers in the prefrontal cortex of rats and provokes depression-like behaviors. Front Neurosci 2017; 11: 209.
    1. Gui WS, Wei X, Mai CL, et al.Interleukin-1β overproduction is a common cause for neuropathic pain, memory deficit, and depression following peripheral nerve injury in rodents. Mol Pain 2016; 12: 1–15. DOI: 10.1177/1744806916646784.
    1. Taylor AMW, Mehrabani S, Liu S, et al.Topography of microglial activation in sensory- and affect-related brain regions in chronic pain. J Neurosci Res 2017; 95: 1330–1335.
    1. Barcelon EE, Cho WH, Jun SB, et al.Brain microglial activation in chronic pain-associated affective disorder. Front Neurosci 2019; 13: 213.
    1. Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science 2016; 354: 572–577.
    1. Rahimifard M, Maqbool F, Moeini-Nodeh S, et al.Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation. Ageing Res Rev 2017; 36: 11–19.
    1. Hore Z, Denk F. Neuroimmune interactions in chronic pain: an interdisciplinary perspective. Brain Behav Immun 2019; 79: 56–62.
    1. Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014; 11: 98.
    1. Vanderwall AG, Milligan ED. Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management. Front Immunol 2019; 10: 3009.
    1. Alboni S, Benatti C, Colliva C, et al.Vortioxetine prevents lipopolysaccharide-induced memory impairment without inhibiting the initial inflammatory cascade. Front Pharmacol 2021; 11: 603979.
    1. de Las Casas-Engel M, Corbí AL. Serotonin modulation of macrophage polarization: inflammation and beyond. Adv Exp Med Biol 2014; 824: 89–115.
    1. Chen F, Danladi J, Ardalan M, et al.The rat hippocampal gliovascular system following one week vortioxetine and fluoxetine. Eur Neuropsychopharmacol 2021; 42: 45–56.
    1. Fiebich B, Akundi R, Lieb K, et al.Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol Suppl 2004; 33: 28–32.
    1. Stratz C, Bhatia HS, Akundi RS, et al.The anti-inflammatory effects of the 5-HT3 receptor antagonist tropisetron are mediated by the inhibition of p38 MAPK activation in primary human monocytes. Int Immunopharmacol 2012; 13: 398–402.
    1. Kim JJ, Bridle BW, Ghia JE, et al.Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol 2013; 190: 4795–4804.
    1. Gupta D, Prabhakar V, Radhakrishnan M. 5HT3 receptors: target for new antidepressant drugs. Neurosci Biobehav Rev 2016; 64: 311–325.
    1. Adamo D, Pecoraro G, Coppola N, et al.Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: an open-label randomized trial. Oral Dis 2021; 27: 1022.
    1. Chen G, Højer AM, Areberg J, et al.Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2018; 57: 673–686.
    1. Guan S, Zou Y, Jia B, et al.Pharmacokinetic and metabolic studies of vortioxetine in rats using ultra high performance liquid chromatography with tandem mass spectrometry. J Sep Sci 2018; 41: 4469–4479.
    1. Dale E, Grunnet M, Pehrson AL, et al.The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: an in vitro study in rat hippocampus slices. Brain Res 2018; 1689: 1–11.
    1. Miao J, Wang G, Hou J, et al.Pharmacokinetics and safety of vortioxetine in the Chinese population. Adv Ther 2019; 36: 3134–3146.
    1. Findling RL, Robb AS, DelBello M, et al.Pharmacokinetics and safety of vortioxetine in pediatric patients. J Child Adolesc Psychopharmacol 2017; 27: 526–534.
    1. Vieta E, Florea I, Schmidt SN, et al.Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019; 34: 153–160.
    1. Areberg J, Søgaard B, Højer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 2012; 111: 198–205.
    1. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al.Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012; 40: 1357–1365.
    1. Spina E, Santoro V. Drug interactions with vortioxetine, a new multimodal antidepressant. Riv Psichiatr 2015; 50: 210–215.
    1. Chen C, Shan W. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: a systematic review and network meta-analysis. Psychiatry Res 2019; 281: 112595.
    1. Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol 2015; 55: 671–679.
    1. McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017; 13: 2913–2919.
    1. de Bartolomeis A, Fagiolini A, Maina G. Vortioxetina nel trattamento della depressione maggiore [Vortioxetine in the treatment of major depression]. Riv Psichiatr 2016; 51: 215–230.
    1. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014; 68: 60–82.
    1. Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol 2018; 8: 13–23.
    1. Jacobsen P, Zhong W, Nomikos G, et al.Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: a randomized, controlled trial. J Sex Med 2019; 16: 1638–1649.
    1. Jacobsen PL, Nomikos GG, Zhong W, et al.Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr 2020; 25: 50–63.
    1. Baldwin DS, Chrones L, Florea I, et al.The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30: 242–252.
    1. Cipriani A, Furukawa TA, Salanti G, et al.Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–1366.
    1. Nissen TD, Laursen B, Viardot G, et al.Effects of vortioxetine and escitalopram on electroencephalographic recordings: a randomized, crossover trial in healthy males. Neuroscience 2020; 424: 172–181.
    1. Wang G, Gislum M, Filippov G, et al.Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin 2015; 31: 785–794.
    1. Nishimura A, Aritomi Y, Sasai K, et al.Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry Clin Neurosci 2018; 72: 64–72.
    1. Thase ME, Mahableshwarkar AR, Dragheim M, et al.A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol 2016; 26: 979–993.
    1. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al.A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry 2015; 76: 583–591.
    1. Jacobsen PL, Mahableshwarkar AR, Serenko M, et al.A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 2015; 76: 575–582.
    1. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013; 29: 217–226.
    1. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al.A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012; 73: 953–959.
    1. Alvarez E, Perez V, Dragheim M, et al.A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15: 589–600.
    1. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012; 28: 1717–1724.
    1. Montgomery SA, Nielsen RZ, Poulsen LH, et al.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014; 29: 470–482.
    1. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29: 138–149.
    1. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27: 215–223.
    1. Alam MY, Jacobsen PL, Chen Y, et al.Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014; 29: 36–44.
    1. Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol 2017; 27: 877–884.
    1. Thase ME, Danchenko N, Brignone M, et al.Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol 2017; 27: 773–781.
    1. Papakostas GI, Nielsen RZ, Dragheim M, et al.Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res 2018; 101: 72–79.
    1. Llorca PM, Lançon C, Brignone M, et al.Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Curr Med Res Opin 2014; 30: 2589–2606.
    1. Wagner G, Schultes MT, Titscher V, et al.Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. J Affect Disord 2018; 228: 1–12.
    1. Meeker AS, Herink MC, Haxby DG, et al.The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015; 4: 21. Published 2015. Mar 1.
    1. Sobieraj DM, Martinez BK, Hernandez AV, et al.Adverse effects of pharmacologic treatments of major depression in older adults. J Am Geriatr Soc 2019; 67: 1571–1581.
    1. Li G, Wang X, Ma D. Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: a meta-analysis of randomized controlled trials. Clin Drug Investig 2016; 36: 509–517.
    1. Christensen MC, Munro V. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Curr Med Res Opin 2018; 34: 593–600.
    1. Florea I, Danchenko N, Brignone M, et al.The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. Clin Ther 2015; 37: 2309–2323.e6.
    1. Pae CU, Wang SM, Han C, et al.Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res 2015; 64: 88–98.
    1. Baldwin DS, Florea I, Jacobsen PL, et al.A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord 2016; 206: 140–150.
    1. Kong W, Deng H, Wan J, et al.Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front Pharmacol 2020; 11: 580858.
    1. Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry 2018; 17: 19.
    1. Perna G, Alciati A, Riva A, et al.Long-term pharmacological treatments of anxiety disorders: an updated systematic review. Curr Psychiatry Rep 2016; 18: 23.
    1. Liebowitz MR, Careri J, Blatt K, et al.Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. Depress Anxiety 2017; 34: 1164–1172.
    1. McIntyre RS, Xiao HX, Syeda K, et al.The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs 2015; 29: 577–589.
    1. Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study. J Affect Disord 2018; 229: 421–428.
    1. Subramaniapillai M, Mansur RB, Zuckerman H, et al.Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with vortioxetine. Compr Psychiatry 2019; 94: 152113.
    1. Lenze EJ, Stevens A, Waring JD, et al.Augmenting computerized cognitive training with vortioxetine for age-related cognitive decline: a randomized controlled trial. Am J Psychiatr 2020; 177: 548–555.
    1. Blumberg MJ, Vaccarino SR, McInerney SJ. Procognitive effects of antidepressants and other therapeutic agents in major depressive disorder. J Clin Psychiatry 2020; 81: 19r13200. Published 2020. Jul 21.
    1. Cao B, Park C, Rosenblat JD, et al.Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: an open-label clinical trial. J Psychopharmacol 2019; 33: 1388–1394.
    1. Liguori C, Ferini-Strambi L, Izzi F, et al.Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol 2019; 85: 240–244.
    1. Adamo D, Pecoraro G, Aria M, et al.Vortioxetine in the treatment of mood disorders associated with burning mouth syndrome: results of an open-label, flexible-dose pilot study. Pain Med 2019; 21: 185–194.
    1. Wilson S, Højer AM, Buchberg J, et al.Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol 2015; 29: 1085–1091.
    1. Matsuno K, Nakamura K, Aritomi Y, et al.Pharmacokinetics, safety, and tolerability of vortioxetine following single- and multiple-dose administration in healthy Japanese adults. Clin Pharmacol Drug Dev 2018; 7: 319–331.
    1. Sutherland AM, Nicholls J, Bao J, et al.Overlaps in pharmacology for the treatment of chronic pain and mental health disorders. Prog Neuropsychopharmacol Biol Psychiatry 2018; 87: 290–297.
    1. Buckman JEJ, Underwood A, Clarke K, et al.Risk factors for relapse and recurrence of depression in adults and how they operate: a four-phase systematic review and meta-synthesis. Clin Psychol Rev 2018; 64: 13–38.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다